Angiotensin II receptor blockers in chronic heart failure-not as ELITE as expected!

Colin A J Farquharson, Aiian D Struthers

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    As with many large-scale long-term outcome trials, more questions have been posed than answered regarding the potential role of angiotensin II receptor blockers as first-line agents in chronic heart failure. Given the present data, in patients with left ventricular systolic dysfunction, ACE inhibitors must remain the treatment of choice, owing to the large body of data supporting their use in this clinical syndrome. However, ARBs seems a reasonable alternative for renin-angiotensin axis blockade in the significant number of heart failure patients who are genuinely intolerant of ACE inhibitors. The pendulum has now swung back in favour of ACE inhibition for chronic heart failure, although one can only await with great expectation the results of the ongoing trials comparing not only angiotensin II receptor blockers with ACE inhibitors but a combination of the two with regards tolerability and survival. Whether this potentially useful class of drugs will ultimately become the cornerstone of heart failure therapy in place of, or in addition to, ACE inhibitors is still in debate, but hopefully we should not have to wait too long for the definitive answers.
    Original languageEnglish
    Pages (from-to)21-22
    Number of pages2
    JournalJournal of the Renin-Angiotensin-Aldosterone System : JRAAS
    Volume1
    Issue number1
    DOIs
    Publication statusPublished - 2000

    Fingerprint

    Angiotensin Receptor Antagonists
    Angiotensin-Converting Enzyme Inhibitors
    Heart Failure
    Angiotensins
    Left Ventricular Dysfunction
    Renin
    Survival
    Therapeutics
    Pharmaceutical Preparations

    Cite this

    @article{83debd6089ac40dba327925a7d67eb8f,
    title = "Angiotensin II receptor blockers in chronic heart failure-not as ELITE as expected!",
    abstract = "As with many large-scale long-term outcome trials, more questions have been posed than answered regarding the potential role of angiotensin II receptor blockers as first-line agents in chronic heart failure. Given the present data, in patients with left ventricular systolic dysfunction, ACE inhibitors must remain the treatment of choice, owing to the large body of data supporting their use in this clinical syndrome. However, ARBs seems a reasonable alternative for renin-angiotensin axis blockade in the significant number of heart failure patients who are genuinely intolerant of ACE inhibitors. The pendulum has now swung back in favour of ACE inhibition for chronic heart failure, although one can only await with great expectation the results of the ongoing trials comparing not only angiotensin II receptor blockers with ACE inhibitors but a combination of the two with regards tolerability and survival. Whether this potentially useful class of drugs will ultimately become the cornerstone of heart failure therapy in place of, or in addition to, ACE inhibitors is still in debate, but hopefully we should not have to wait too long for the definitive answers.",
    author = "Farquharson, {Colin A J} and Struthers, {Aiian D}",
    year = "2000",
    doi = "10.3317/jraas.2000.003",
    language = "English",
    volume = "1",
    pages = "21--22",
    journal = "Journal of the Renin-Angiotensin-Aldosterone System : JRAAS",
    issn = "1470-3203",
    publisher = "SAGE Publications",
    number = "1",

    }

    Angiotensin II receptor blockers in chronic heart failure-not as ELITE as expected! / Farquharson, Colin A J; Struthers, Aiian D.

    In: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS, Vol. 1, No. 1, 2000, p. 21-22.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Angiotensin II receptor blockers in chronic heart failure-not as ELITE as expected!

    AU - Farquharson, Colin A J

    AU - Struthers, Aiian D

    PY - 2000

    Y1 - 2000

    N2 - As with many large-scale long-term outcome trials, more questions have been posed than answered regarding the potential role of angiotensin II receptor blockers as first-line agents in chronic heart failure. Given the present data, in patients with left ventricular systolic dysfunction, ACE inhibitors must remain the treatment of choice, owing to the large body of data supporting their use in this clinical syndrome. However, ARBs seems a reasonable alternative for renin-angiotensin axis blockade in the significant number of heart failure patients who are genuinely intolerant of ACE inhibitors. The pendulum has now swung back in favour of ACE inhibition for chronic heart failure, although one can only await with great expectation the results of the ongoing trials comparing not only angiotensin II receptor blockers with ACE inhibitors but a combination of the two with regards tolerability and survival. Whether this potentially useful class of drugs will ultimately become the cornerstone of heart failure therapy in place of, or in addition to, ACE inhibitors is still in debate, but hopefully we should not have to wait too long for the definitive answers.

    AB - As with many large-scale long-term outcome trials, more questions have been posed than answered regarding the potential role of angiotensin II receptor blockers as first-line agents in chronic heart failure. Given the present data, in patients with left ventricular systolic dysfunction, ACE inhibitors must remain the treatment of choice, owing to the large body of data supporting their use in this clinical syndrome. However, ARBs seems a reasonable alternative for renin-angiotensin axis blockade in the significant number of heart failure patients who are genuinely intolerant of ACE inhibitors. The pendulum has now swung back in favour of ACE inhibition for chronic heart failure, although one can only await with great expectation the results of the ongoing trials comparing not only angiotensin II receptor blockers with ACE inhibitors but a combination of the two with regards tolerability and survival. Whether this potentially useful class of drugs will ultimately become the cornerstone of heart failure therapy in place of, or in addition to, ACE inhibitors is still in debate, but hopefully we should not have to wait too long for the definitive answers.

    U2 - 10.3317/jraas.2000.003

    DO - 10.3317/jraas.2000.003

    M3 - Article

    C2 - 11967790

    VL - 1

    SP - 21

    EP - 22

    JO - Journal of the Renin-Angiotensin-Aldosterone System : JRAAS

    JF - Journal of the Renin-Angiotensin-Aldosterone System : JRAAS

    SN - 1470-3203

    IS - 1

    ER -